Pulse Biosciences Files 8-K
Ticker: PLSE · Form: 8-K · Filed: Oct 10, 2025 · CIK: 1625101
| Field | Detail |
|---|---|
| Company | Pulse Biosciences, Inc. (PLSE) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
TL;DR
Pulse Biosciences filed an 8-K on 10/10/25. Standard reporting.
AI Summary
Pulse Biosciences, Inc. filed an 8-K on October 10, 2025, reporting other events and financial statements. The company, formerly known as Electroblate, Inc., is incorporated in Delaware and headquartered in Hayward, California.
Why It Matters
This filing indicates routine corporate reporting, providing updates on company events and financial disclosures to investors.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for corporate events and financial statements, not indicating any specific new risks.
Key Numbers
- 001-37744 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- Pulse Biosciences, Inc. (company) — Registrant
- Electroblate, Inc. (company) — Former company name
- October 10, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 465696597 (tax_id) — IRS Employer Identification No.
- 510-906-4600 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 10, 2025.
When was the earliest event reported in this filing?
The earliest event reported was on October 10, 2025.
What is the principal executive office address of Pulse Biosciences, Inc.?
The address of the principal executive offices is 601 Brickell Key Drive, Suite 1080, Miami, Florida, 33131.
What were Pulse Biosciences, Inc.'s former company names?
Pulse Biosciences, Inc. was formerly known as Pulse Biosciences, Inc. (after a name change on December 10, 2015) and prior to that, as Electroblate, Inc. (after a name change on November 13, 2014).
What is the SIC code for Pulse Biosciences, Inc.?
The Standard Industrial Classification (SIC) code for Pulse Biosciences, Inc. is 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2025-10-10 09:02:17
Key Financial Figures
- $0.001 — nge on Which Registered Common stock , $0.001 par value per share PLSE The Nasdaq
Filing Documents
- plse20251009_8k.htm (8-K) — 26KB
- ex_868565.htm (EX-99.1) — 14KB
- 0001437749-25-030816.txt ( ) — 173KB
- plse-20251010.xsd (EX-101.SCH) — 3KB
- plse-20251010_def.xml (EX-101.DEF) — 11KB
- plse-20251010_lab.xml (EX-101.LAB) — 15KB
- plse-20251010_pre.xml (EX-101.PRE) — 11KB
- plse20251009_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On October 10, 2025, Pulse Biosciences, Inc. (the "Company") issued a press release announcing late-breaking clinical study results from its nPulse Cardiac Surgical System first-in-human feasibility study. To date, 44 patients have been treated by three investigators in the study. In the initial cohort, twenty-four patients have had the ablation effectiveness and durability evaluated by electroanatomical mapping at approximately three months post the ablation procedure. Initial cohort study results include: All (100%) posterior box isolations were acutely successful in the high-dose cohort Success rate of PVI (per vein) at ~3 months was 94% (63/67) Average total ablation time of 50 seconds with average number of 13 applications No reports of esophageal or phrenic nerve damage No ablation-related severe or major adverse events A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Pulse Biosciences, Inc. dated October 10, 2025 - Pulse Biosciences Announces Presentation of Late-Breaking Data from the nPulse Cardiac Surgical System First-In-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: October 10, 2025 By: /s/ Paul A. LaViolette Paul LaViolette Chief Executive Officer (Principal Executive Officer)